Hereditary multiple exostosis (HME, also called EXT) is an autosomal dominant disorder characterized by the presence of multiple exostoses (osteochondromas) localized mainly in the juxtaepiphyseal region of long, tubular bones. These osteochondromas are apparent during the first decade of life in more than 80% of the patients (Solomon, 1963) . The estimated prevalence of EXT ranges from 1.3/100 000 (Hennekam, 1991) to 2/100 000 (Schmale et al, 1994) . Penetrance is estimated between 66% (Suyiura et al, 1976) and 100% (Wicklund et al, 1995) . An exostosis can transform into a chondrosarcoma or an osteosarcoma in about 0.9% to 2.9% of EXT-patients. Other features include short stature, limb length inequalities, nerve and blood vessel compression, impaired articular function, bowing of tubular bones and synostoses (Wicklund et al, 1995) .
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EXT is a genetically heterogeneous disease with at least 3 susceptibility loci. 2 of them, the EXT1 gene on chromosome 8q24.1 and the EXT2 gene on chromosome 11p11 have been isolated by positional cloning (Ahn et al, 1995; Stickens et al, 1996; Wuyts et al, 1996) . Since loss of heterozygosity (LOH) has been observed with markers linked to the EXT1 or EXT2 genes in both sporadic and exostoses-derived tumour materials, it has been suggested that the EXT genes might be tumour suppressor genes Raskind et al, 1995) . The EXT3 gene has been mapped to 19p (Le Merrer et al, 1996) . In addition, 3 EXT-like genes have been mapped, namely EXTL1 on 1p36 (Wise et al, 1997) , EXTL2 on 1p11-12 (Wuyts et al, 1997) and EXTL3 on 8p12-22 . They all encode products with the homologue C-terminals. Although the EXTL genes are considered strong candidate genes for EXT, most of the EXT patients are linked with EXT1 and EXT2 and so far no EXTL mutation has been detected in any EXT patient.
We now analysed a large Chinese EXT pedigree with at least 38 affected members. After linkage analysis and mutation analysis, a novel mutation, namely, a deletion of one nucleotide in exon 3 of the EXT2 gene was observed.
MATERIALS AND METHODS

EXT family
Blood or saliva specimen were collected from 69 members of a Chinese multigeneration pedigree with hereditary multiple exostoses with the informed consent of the participants. Among them, 23 were affected.
Genomic DNA was extracted from peripheral blood lymphocytes by salting-out method (Miller et al, 1988) , or from mouth swabs by Chelex method (Walsh et al, 1991) . Mouth swabs were collected by firm rubbing of a cotton bud backwards and forwards between the cheek and gum several times (3 cotton buds were used for each individual).
Linkage analysis
Linkage analysis was carried out using the LINKAGE 5.1 package program MLINK (Lathrop et al, 1984) for 2-point analysis, assuming dominant inheritance with full penetrance and EXT frequency set to 1/50 000. Microsatellite repeat markers were selected according to literature (Tang et al, 1998) . D8S85, D8S285 and D8S199 from 8q24.1 (EXT1), D11S903, D11S1361 and D11S1355 from 11p11 (EXT2) and D19S221 from 19p(EXT3) were studied.
Mutational screening
After linkage was suggested to the EXT2 gene, exons 2 to 14 of the EXT2 gene were amplified by using PCR profiles from Wuyts et al (1998) with slight modification.
The sequences of the primers were shown in Table 1 . Exon 2 was split into 3 overlapping fragments to obtain amplification products suitable for SSCP analysis. PCR was performed in a 25 µl reaction volume, containing 50-100 ng of genomic DNA, 1 × PCR buffer, 200 µM of each dNTP, 0.4 µM of each primer pair, 1.5 mM of MgCl 2 and 1 unit of Taq DNA polymerase (GENETAQ). PCR was carried out in Perkin Elmer 9600 thermal cycler. After predenaturation at 95°C for 5 min, the PCR was carried out for 30-35 cycles of denaturation at 94°C for 30 s, annealing at suitable temperature for 30 s, extension at 72°C for 30 s, and a final extension at 72°C for 5 min. The annealing temperature was 55°C for all primer pairs, with the exception of primer pairs amplifying exons 3, 5 and 10, for which the annealing temperature was changed to 51°C. The amplified products were then subjected to agarose gel eletrophoresis to judge their amplification efficiency. Finally, SSCP of the amplified products was performed according to standard protocol, and the gel was silver stained and analysed.
The PCR fragments containing aberrant fragments (i.e. exon 3) were reamplified, and then either purified by use of PCR Clean Up Kit (Boehringer Mannheim) and directly sequenced by using Cy5 dye-terminator thermal sequenase sequencing kit (Pharmacia Biotech); or cloned into pGEM T-easy vector (Promega), and the identified double strand plasmids were then sequenced by using ABI Prism DNA sequencing kit (PE). Sequencing reactions were performed according to the instructions by the kit supplier. For PCR products sequencing, one of the amplification primers for exon 3 was used as sequencing primer, and sequences were analysed on ALF express automatic DNA sequencer (Pharmacia Biotech); for plasmid sequencing, M13 reverse primer was used as sequencing primer, and sequences were analysed on AB1 377 automatic DNA sequencer (PE).
RESULTS
Clinical description of the family
In the whole family, according to the anamnesis of some family members, at least 35 individuals were severely affected with multiple large exostoses, some of them were more than 10 cm in diameter, 3 (V51, V56 and VI25 in Figure 1 ) were slightly affected, with only a isolated small exostosis less than 1 cm in diameter. Among the severely affected at least in 4 individuals including the proband (IV53, the first patient observed by doctor in the family) an exostosis has transformed into chondrosarcoma. The pedigree is shown in Figure 1 . The diagnosis of the disease in the family was made by osteologists at the First Affiliated Hospital of West China University of Medical Sciences. Some of the patients have been confirmed by regional X-radiographic analysis. In addition, the proband's diagnosis was made also by biopsy of the exostosis. Clinically all the severely affected members were of short stature with mean height of less than 155 cm in male patients, and had multiple exostoses at the metaphyses of the long tubular bones, some of them even had 30-40 exostoses all over the body. The local appearance and radiological findings in some severely affected members are shown in Figure 2 . The proband noticed her first exostosis of about 1 cm in diameter at her left pubis when she was 33 years old. The exostosis grew slowly to about 2 cm 2 years later. Then an operation was performed to remove this exostosis and biopsy of the removed exostosis was performed. But 1 year after, the exostosis recurred, grew rapidly and became painful, then the tumour malignantly transformed to well-differentiated chondrosarcoma, which was confirmed by biopsies of the removed tissues at least 7 times during the following years. The chondrosarcomas then metastasized to the soft tissues close to spinal column of abdomen and several other sites in her pelvis, so an extended hemipelvectomy was performed. In the following 11 years she has had more than 7 operations to remove the recurred chondrosarcomas. Similarly malignant transformation in another 3 severely affected members had occurred after accidental injury of one of the exostosis.
Linkage analysis
All the 3 markers from 11p11 (EXT2) gave a 2-point LOD-score value of >3 and showed no recombination between the markers and the EXT phenotype, therefore the linkage between the exostoses and EXT2 gene was firmly established in the large family. The markers from 8q24 and 19p gave very low LOD-score of <1, so the linkage to EXT1 and EXT3 can be ignored. According to this result, the family's EXT is linked to EXT2 was concluded.
Mutation analysis
SSCP analysis of exon 3 of all the family members revealed that all severely affected members showed the same pattern with 2 additional single-strand bands as compared with the unaffected members and the unrelated healthy members in the family, suggesting that in the severely affected patients the 2 alleles of the exon 3 of EXT2 gene are different. However, in 2 of the slightly affected individuals (V 51 and VI 25), no additional single strand bands were observed. Figure 3 shows SSCP results of some of the members in the family. Exon 3 of 3 different severely affected members, one slightly affected member and one unrelated healthy individual were sequenced. In all the 3 severely affected patients, there was a deletion of 'G' at the position 431 of U67357, corresponding to position 561 (no. 1 is corresponding to the 'A' in the initiation codon in U64511) in the mRNA sequence (Figure 4) . But no such deletion was observed in the slightly affected member, neither was in the unrelated healthy individual.
DISCUSSION
In the present large family a heterozygous deletion of a 'G' in exon 3 of EXT2 gene likely represents the causative defect. It results in frameshift and premature stop codon that would lead to the 48  49  50  51  52  53  54  55  56  57  58  59  60  6  1  6  2  6   3  6   4  6  5  6  6   6  7  6  8  6  9  7  0  7  1  7  2  7  3  7  4   7  5  76  77   78  79  80  81  82  83  84 EXT1 and EXT2 genes are putative tumour suppressor genes (Ahn et al, 1995; Hecht et al, 1995; Raskind et al, 1995) . It has been reported that proteins encoded by these genes, are endoplasmic reticulum-localized type II transmembrane glycoproteins that possess or are tightly associated with glycosyltransferase activities in the polymerization of heparan sulfate (Lind et al, 1998; McCormick et al, 2000) . EXT2 does not harbour significant glycosyltransferase activity in the absence of EXT1. Instead, IV8  IV11  IV13  IV19  V13  V17  V21  V23  V28  V32  V35  V39  V40  V43  V44  V46  VI7  VI8  VI9  VI10  VI11  VI12  VI13  VI15  VI16  VI17  VI18  VI19  VI20 VI21 VI22
Figure 3 SSCP of the exon 3 of EXT2 gene in some of the pedigree members. IV13, V28, V35, VI15, VI16 and VI18 are severely affected patients and IV11 is a carrier, and in these persons besides the 2 normal single-stranded bands, 2 additional single-stranded bands are observed. The others are healthy members in the family, in which only 2 single-stranded bands are observed EXT1 and EXT2 form a hetero-oligomeric complex in vivo that leads to the accumulation of both proteins in the Golgi apparatus. Remarkably, the Golgi-localized EXT1/EXT2 complex possesses substantially high glycosyltransferase activity than EXT1 or EXT2 alone, suggesting that the complex represents the biologically relevant form of the enzyme(s). These can easily explain how inherited mutations in either of the two EXT genes can give rise to hereditary multiple exostoses (McCormick et al, 2000) . Since the identification of EXT1 and EXT2 genes, there have been many different mutations reported. Among them at least 49 different EXT1 and 25 different EXT2 mutations have been detected in EXT patients, and there is evidence that mutations in these 2 genes are responsible for over 70% of the EXT cases (Wuyts and Van Hul, 2000) . Among the 49 EXT1 mutations, 9 are nonsense, 21 frameshift and 5 splice site mutations, 2 in-frame deletions with 1 and 5 amino acids respectively, and 12 missense mutations. The 25 EXT2 mutations include 8 nonsense, 11 frameshift, 3 splice site and 3 missense mutations. The deletion of one nucleotide described in present study has not been described before.
It is interesting to note that in the studied family, there are at least 3 affected members who develop only a single exostosis, and 2 of them are in their 30s, the third one is 10. In 2 of these 3 slightly affected patients (V51 and VI25, the third one's blood sample was not available), SSCP analysis of exon 3 failed to detect the same two additional single strand bands as seen in other severely affected ones. This implies that they might be cases of phenocopy, or alternatively, the causative gene abnormality in these 3 individuals may be different from that of the others in the pedigree, although that 2 different mutations in same family is scarce. However, whatever the reason is, the interesting feature makes genetic counselling of the patients more complicated.
According to the genotype-phenotype correlation, the penetrance of EXT in the family is not complete. There is one member (IV11), whose daughter and granddaughter are affected, carries the 2 additional single strand bands in SSCP, hence the mutation, but displays no any visible exostoses.
According to literature, the general recommended treatment to symptomatic exostoses or dislocated radial heads is to remove them. Surgery can improve aesthetic appearance and relieve the pain when done before or after skeletal maturity (Arms et al, 1997; Porter et al, 2000; Vasseur and Fabre, 2000) . It seems that the tumour does not interfere with the longevity of the patients and several affected individuals in this family live up to their 80s to 90s. Whether surgical removal of the exostoses is responsible for the progression to malignancy is not clear. It is possible that some unknown factors including some modifying genes may play an important role in the malignant transformation.
